Association of polymorphisms in intron 2 of FGFR2 and breast cancer risk in Chinese women
- Authors: Pan Z.1, Bao Y.1, Zheng X.1, Cao W.2, Cheng W.1, Xu X.1
-
Affiliations:
- Clinical Laboratory Department
- Department of Medical Oncology
- Issue: Vol 50, No 5 (2016)
- Pages: 312-317
- Section: Article
- URL: https://journals.rcsi.science/0095-4527/article/view/173442
- DOI: https://doi.org/10.3103/S009545271605008X
- ID: 173442
Cite item
Abstract
Recent genome-wide association studies (GWAS) demonstrated that genetic variation in intron 2 of fibroblast growth factor receptor 2 (FGFR2) was a novel risk for breast cancer. We investigated whether two SNPs rs1219648 and rs2981582 in intron 2 of FGFR2 were associated with the risk of breast cancer in Chinese women. A total of 340 female breast cancer patients and 400 normal age-matched controls were recruited. Two SNPs were genotyped using matrix-assisted laser desorption/ionization mass spectrometry. The two SNPs rs1219648 and rs2981582 showed no association with the risk of breast cancer. A subgroup analysis by menopausal status demonstrated that the distribution of rs2981582 T alleles, including CT and TT genotypes, was significantly higher in premenopausal patients compared with postmenopausal patients. The TT genotype in rs2981582 was more strongly associated with ER-positive than with ER-negative tumors by ER status analysis. Analysis by haplotypes showed that no haplotypes associated with breast cancer. The results showed no association between two SNPs, rs1219648 and rs2981582 and breast cancer risk, although in a stratified analysis rs2981582 strongly associated with premenopausal and ER-positive breast cancer patients in Chinese women.
About the authors
Z. Pan
Clinical Laboratory Department
Email: zjhzxxh@163.com
China, Hangzhou
Y. Bao
Clinical Laboratory Department
Email: zjhzxxh@163.com
China, Hangzhou
X. Zheng
Clinical Laboratory Department
Email: zjhzxxh@163.com
China, Hangzhou
W. Cao
Department of Medical Oncology
Email: zjhzxxh@163.com
China, Hangzhou
W. Cheng
Clinical Laboratory Department
Email: zjhzxxh@163.com
China, Hangzhou
X. Xu
Clinical Laboratory Department
Author for correspondence.
Email: zjhzxxh@163.com
China, Hangzhou